Baird Upgrades Alexion Pharmaceuticals (NASDAQ:ALXN) to "Outperform"

Marco Green
January 14, 2018

It has underperformed by 1.21% the S&P500. Icm Asset Management Inc sold 116,895 shares as the company's stock declined 1.76% while stock markets rallied.

Bridger Management Llc, which manages about $3.11 billion and $1.67B US Long portfolio, decreased its stake in Impax Laboratories Inc (NASDAQ:IPXL) by 738,687 shares to 602,456 shares, valued at $12.23 million in 2017Q3, according to the filing.

Ownership at Alexion Pharmaceuticals, Inc. The stock increased 0.52% or $0.225 during the last trading session, reaching $43.125. About 602,262 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since January 11, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

Among 28 analysts covering Alexion Pharmaceuticals Inc. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty have given a buy rating to the company. Therefore 23% are positive. Alexion Pharmaceuticals's revenue was up 7.5% on a year-over-year basis. analysts anticipate that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current year. The firm has "Buy" rating given on Tuesday, October 24 by Leerink Swann. Piper Jaffray Companies set a $176.00 price objective on Alexion Pharmaceuticals and gave the company a "buy" rating in a research note on Sunday, November 6th. BMO Capital Markets reissued an "outperform" rating and issued a $173.00 target price (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Goldman Sachs upgraded the shares of ALXN in report on Friday, October 28 to "Buy" rating. The company was initiated on Friday, September 23 by Wedbush. (NASDAQ:ALXN) earned "Equal-Weight" rating by Barclays Capital on Thursday, February 4. (NASDAQ:ALXN) has "Outperform" rating given on Friday, July 28 by BMO Capital Markets. Finally, Deutsche Bank AG initiated coverage on Alexion Pharmaceuticals in a research note on Thursday, November 3rd. (NASDAQ:ALXN) on Monday, December 18 to "Outperform" rating. (NASDAQ:ALXN) to report earnings on February, 15. They expect $1.08 earnings per share, down 1.82 % or $0.02 from last year's $1.1 per share. The Pioneer Investment Management Inc holds 77,110 shares with $10.82 million value, up from 52,228 last quarter.

Since July 31, 2017, it had 0 insider purchases, and 6 selling transactions for $2.74 million activity. (NASDAQ:ALXN) for 4,398 shares. 11,160 shares were sold by O'Neill Julie, worth $1.56M on Monday, August 28. (NASDAQ:ALXN) shares were sold by Wagner Heidi L. (NASDAQ:ALXN) on Monday, October 2.

By looking at a stock's average trade volume - in the short, medium, and long terms - we can gain a better understanding of investor sentiment and trading activity.

Menora Mivtachim Holdings Ltd. holds 0.06% of its portfolio in Pluristem Therapeutics Inc. for 1.00 million shares. Finally, Evercore Wealth Management LLC raised its position in shares of Alexion Pharmaceuticals by 5.0% in the second quarter. (NASDAQ:ALXN). 385,698 are held by Adage Capital Ptnrs Grp Lc. Oakbrook Investments Ltd Liability Company owns 16,475 shares for 0.15% of their portfolio. Paradigm Asset Limited Co has invested 0.02% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). 2,078 are held by Mackenzie Finance. Of those holders, 305 had increased positions amounting to 16.15 million shares, 260 had decreased positions amounting to 15.67 million shares, and 77 holders have a held position accounting for 179.84 million shares. Bank Of America Corp De, a North Carolina-based fund reported 128 shares. 2,280 are owned by Chicago Equity Prtn Ltd Liability Com. Virtu Ltd, a New York-based fund reported 30,535 shares. (NASDAQ:ALXN). Da Davidson Com stated it has 0.01% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 2,553 shares. Orbimed Advisors Llc who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be less bullish one the $27.36 billion market cap company.

A number of equities analysts recently commented on ALXN shares. Sumitomo Mitsui Holding holds 626,693 shares.

Investors sentiment decreased to 1 in Q3 2017. 118.53 million shares or 0.58% less from 119.22 million shares in 2017Q2 were reported. It is positive, as 32 investors sold UNFI shares while 70 reduced holdings. Commonwealth Equity Services invested in 7,544 shares. (NASDAQ:ALXN). Btg Pactual Global Asset Management holds 0.16% or 3,640 shares in its portfolio. Savings Bank Of The West reported 82,733 shares.

When thinking about buying shares in a public company, it is useful to gauge the average enthusiasm level of Wall Street analysts for that specific stock. Lombard Odier Asset Mngmt (Switzerland) Sa holds 23,640 shares.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. (NASDAQ:UNFI). Sei owns 18,767 shares or 0% of their U.S. portfolio. Stevens Management Limited Partnership stated it has 13,981 shares. Morgan Stanley has invested 0% in Southern First Bancshares, Inc. (NASDAQ:UNFI) for 17,936 shares. Moreover, State Of Wisconsin Invest Board has 0.02% invested in United Natural Foods, Inc. (ALXN) delivered a 8.93% earnings surprise. They expect $1.08 EPS, down 1.82% or $0.02 from last year's $1.1 per share. UNFI's profit will be $26.72 million for 21.69 P/E if the $0.53 EPS becomes a reality. After $0.07 actual earnings per share reported by IAMGOLD Corporation for the previous quarter, Wall Street now forecasts -57.14% negative EPS growth. (NYSE:V) shares were sold by MATSCHULLAT ROBERT W. 49,702 shares were sold by MAHON TULLIER KELLY, worth $5.65M on Friday, December 15. Volume approached 3.3 million shares vs. average over the past 3 months of 2.93 million shares. (NASDAQ:HALO) rating on Friday, September 16. The stock was sold at an average price of $121.63, for a total value of $310,521.39. CRANSTON MARY B also sold $1.07M worth of Visa Inc.

Zacks Investment Management decreased Cna Finl Corp (NYSE:CNA) stake by 18,036 shares to 19,549 valued at $982,000 in 2017Q3. It also increased its holding in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 20,000 shares in the quarter, for a total of 50,000 shares, and has risen its stake in Edwards Lifesciences Corp (Put) (NYSE:EW).

Other reports by Click Lancashire

Discuss This Article